Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
November 02, 2011
Study Finds Genomic/Clinical Combo to Be Best Predictor of Complications in Stent Patients on Plavix
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Canadian Team Validates Spartan's Point-of-Care CYP2C19 Test to Personalize Anti-Platelet Treatment
November 30, 2011 / Pharmacogenomics Reporter - New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
September 1, 2010 / Pharmacogenomics Reporter - FDA Issues Boxed Warning for CYP2C19-Linked Poor Metabolism of Plavix
March 17, 2010 / Pharmacogenomics Reporter - Study Points to Role of ABCB1 Gene Alterations in Plavix-Treated Patients' Cardiovascular AEs
March 17, 2010 / Pharmacogenomics Reporter - Ahead of Pending Studies on PGx-Based Plavix Administration, Is Quest/Scripps CYP2C19 Testing Alliance Premature?
October 28, 2009 / Pharmacogenomics Reporter